BIIB - Assessing Biogen's Performance Against Competitors In Biotechnology Industry | Benzinga
Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Biogen (NASDAQ:BIIB) in comparison to its major competitors within the Biotechnology industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Biogen Background
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Biogen Inc | |||||||
| 12.79 | |||||||
| 2.35 | |||||||
| 3.42 | |||||||
| 4.19% | |||||||
| $0.87 | |||||||
| $1.86 | |||||||
| -5.14% | |||||||
| AbbVie Inc | |||||||
| 28.59 | |||||||
| 19.06 | |||||||
| 4.40 | |||||||
| 15.4% | |||||||
| $5.42 | |||||||
| $9.62 | |||||||
| -4.92% | |||||||
| Amgen Inc | |||||||
| 17.63 | |||||||
| 20.63 | |||||||
| 5.29 | |||||||
| 22.74% | |||||||
| $3.26 | |||||||
| $5.17 | |||||||
| 5.94% | |||||||
| Gilead Sciences Inc | |||||||
| 17.61 | |||||||
| 4.51 | |||||||
| 3.53 | |||||||
| 4.96% | |||||||
| $2.5 | |||||||
| $5.16 | |||||||
| 5.42% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 27.46 | |||||||
| 5.93 | |||||||
| 9.72 | |||||||
| 6.12% | |||||||
| $1.21 | |||||||
| $2.18 | |||||||
| 13.52% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 20.51 | |||||||
| 3.51 | |||||||
| 6.96 | |||||||
| 4.08% | |||||||
| $1.2 | |||||||
| $2.75 | |||||||
| 10.53% | |||||||
| Moderna Inc | |||||||
| 24.97 | |||||||
| 1.61 | |||||||
| 2.71 | |||||||
| -7.71% | |||||||
| $-1.64 | |||||||
| $-0.41 | |||||||
| -93.08% | |||||||
| BioNTech SE | |||||||
| 4.78 | |||||||
| 1.04 | |||||||
| 2.28 | |||||||
| -0.95% | |||||||
| $-0.38 | |||||||
| $-0.37 | |||||||
| -94.75% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 155.13 | |||||||
| 3.17 | |||||||
| 6.89 | |||||||
| 1.19% | |||||||
| $0.1 | |||||||
| $0.47 | |||||||
| 11.52% | |||||||
| Incyte Corp | |||||||
| 32.23 | |||||||
| 2.48 | |||||||
| 3.37 | |||||||
| 4.42% | |||||||
| $0.3 | |||||||
| $0.89 | |||||||
| 4.74% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 59.60 | |||||||
| 5.59 | |||||||
| 6.43 | |||||||
| 5.4% | |||||||
| $0.13 | |||||||
| $0.44 | |||||||
| 19.7% | |||||||
| United Therapeutics Corp | |||||||
| 12.42 | |||||||
| 1.90 | |||||||
| 5.13 | |||||||
| 4.92% | |||||||
| $0.36 | |||||||
| $0.53 | |||||||
| 27.76% | |||||||
| Exelixis Inc | |||||||
| 40.42 | |||||||
| 2.55 | |||||||
| 3.84 | |||||||
| 3.19% | |||||||
| $0.08 | |||||||
| $0.45 | |||||||
| 12.02% | |||||||
| Grifols SA | |||||||
| 43.37 | |||||||
| 0.86 | |||||||
| 0.78 | |||||||
| 1.02% | |||||||
| $0.25 | |||||||
| $0.62 | |||||||
| 7.81% | |||||||
| Average | |||||||
| 37.29 | |||||||
| 5.6 | |||||||
| 4.72 | |||||||
| 4.98% | |||||||
| $0.98 | |||||||
| $2.12 | |||||||
| -5.68% |